David B Teplow

List of Publications by Year
in descending order

133 papers	23,262 citations	11235 73 h-index	17891 125 g-index
142 all docs	142 docs citations	142 times ranked	16921 citing authors

#	Article	IF	Citations
1	From reaction kinetics to dementia: A simple dimer model of Alzheimerâ€™s disease etiology. PLoS Computational Biology, 2021, 17, e1009114.	1.5	7
2	Myricetin prevents high molecular weight AÎ²1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. Free Radical Biology and Medicine, 2021, 171, 232-244.	1.3	27
3	Ultrasensitive amyloid Î²â€protein quantification with high dynamic range using a hybrid grapheneâ€“gold surfaceâ€enhanced Raman spectroscopy platform. Journal of Raman Spectroscopy, 2020, 51, 432-441.	1.2	8
4	Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease. Brain, 2020, 143, 336-358.	3.7	52
5	Self- and Cross-Seeding on Î±-Synuclein Fibril Growth Kinetics and Structure Observed by High-Speed Atomic Force Microscopy. ACS Nano, 2020, 14, 9979-9989.	7.3	28
6	Effects of IL-34 on Macrophage Immunological Profile in Response to Alzheimer's-Related AÎ²42 Assemblies. Frontiers in Immunology, 2020, 11, 1449.	2.2	15
7	High molecular weight amyloid Î² 1â€42 oligomers induce neurotoxicity via plasma membrane damage. Alzheimer's and Dementia, 2020, 16, e037546.	0.4	3
8	Vitamin B12 may prevent AÎ² oligomerâ€induced neurotoxicity in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e045043.	0.4	0
9	Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related AÎ²42 Oligomers and Protect Synapses. Frontiers in Immunology, 2020, 11, 49.	2.2	32
10	Preface. Progress in Molecular Biology and Translational Science, 2019, 164, xiii-xvi.	0.9	0
11	High molecular weight amyloid Î² _{1â€42} oligomers induce neurotoxicity via plasma membrane damage. FASEB Journal, 2019, 33, 9220-9234.	0.2	72
12	Surface enhanced Raman spectroscopy distinguishes amyloid Î²â€protein isoforms and conformational states. Protein Science, 2018, 27, 1427-1438.	3.1	29
13	A novel role for osteopontin in macrophage-mediated amyloid-Î² clearance in Alzheimerâ€™s models. Brain, Behavior, and Immunity, 2018, 67, 163-180.	2.0	86
14	Preparation of Pure Populations of Amyloid Î²-Protein Oligomers of Defined Size. Methods in Molecular Biology, 2018, 1779, 3-12.	0.4	6
15	Using chirality to probe the conformational dynamics and assembly of intrinsically disordered amyloid proteins. Scientific Reports, 2017, 7, 12433.	1.6	37
16	Identification of key regions and residues controlling AÎ² folding and assembly. Scientific Reports, 2017, 7, 12434.	1.6	20
17	Nanoscale Dynamics of Amyloid Î²-42 Oligomers As Revealed by High-Speed Atomic Force Microscopy. ACS Nano, 2017, 11, 12202-12209.	7.3	85
18	A Critical Role of Ser26 Hydrogen Bonding in AÎ²42 Assembly and Toxicity. Biochemistry, 2017, 56, 6321-6324.	1.2	3

#	Article	IF	Citations
19	Pittsburgh Compoundâ€B (PiB) binds amyloid Î²â€protein protofibrils. Journal of Neurochemistry, 2017, 140, 210-215.	2.1	33
20	Preparation of pure populations of covalently stabilized amyloid Î²-protein oligomers of specific sizes. Analytical Biochemistry, 2017, 518, 78-85.	1.1	26
21	Aggregation of Chameleon Peptides: Implications of Î±-Helicity in Fibril Formation. Journal of Physical Chemistry B, 2016, 120, 5874-5883.	1.2	22
22	High-speed atomic force microscopy reveals structural dynamics of amyloid Î² _{1â€“42} aggregates. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5835-5840.	3.3	179
23	Design, Characterization, and Use of a Novel Amyloid Î²-Protein Control for Assembly, Neurotoxicity, and Gene Expression Studies. Biochemistry, 2016, 55, 5049-5060.	1.2	5
24	Amyloid Î²-Protein Assembly and Alzheimerâ€™s Disease: Dodecamers of AÎ²42, but Not of AÎ²40, Seed Fibril Formation. Journal of the American Chemical Society, 2016, 138, 1772-1775.	6.6	123
25	Synaptic Amyloid-Î² Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. American Journal of Pathology, 2016, 186, 185-198.	1.9	94
26	Amyloid Î²-Protein C-Terminal Fragments: Formation of Cylindrins and Î²-Barrels. Journal of the American Chemical Society, 2016, 138, 549-557.	6.6	91
27	Inhibiting amyloid Î²â€protein assembly: Sizeâ€“activity relationships among grape seedâ€derived polyphenols. Journal of Neurochemistry, 2015, 135, 416-430.	2.1	28
28	O2-05-05: Rescue of synapses with glatiramer acetate immunotherapy in a murine model of Alzheimer's disease. , 2015, 11, P185-P185.		0
29	Na, K-ATPase Î±3 is a death target of Alzheimer patient amyloid-Î² assembly. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4465-74.	3.3	112
30	Design and Characterization of Chemically Stabilized AÎ²42 Oligomers. Biochemistry, 2015, 54, 5315-5321.	1.2	13
31	Role of Species-Specific Primary Structure Differences in AÎ²42 Assembly and Neurotoxicity. ACS Chemical Neuroscience, 2015, 6, 1941-1955.	1.7	26
32	Amyloid Î²-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimerâ€™s Disease Mutation. ACS Chemical Neuroscience, 2015, 6, 1732-1740.	1.7	55
33	Gly25-Ser26 Amyloid Î²-Protein Structural Isomorphs Produce Distinct AÎ²42 Conformational Dynamics and Assembly Characteristics. Journal of Molecular Biology, 2014, 426, 2422-2441.	2.0	30
34	Factors That Drive Peptide Assembly from Native to Amyloid Structures: Experimental and Theoretical Analysis of [Leu-5]-Enkephalin Mutants. Journal of Physical Chemistry B, 2014, 118, 7247-7256.	1.2	26
35	Nanoprobing of the Effect of Cu2+ Cations on Misfolding, Interaction and Aggregation of Amyloid Î² Peptide. Journal of NeuroImmune Pharmacology, 2013, 8, 262-273.	2.1	40
36	C-Terminal Turn Stability Determines Assembly Differences between AÎ²40 and AÎ²42. Journal of Molecular Biology, 2013, 425, 292-308.	2.0	73

#	Article	IF	Citations
37	Biophysical Characterization of AÎ² Assembly. Modecular Medicine and Medicinal, 2013, , 83-125.	0.4	1
38	On the subject of rigor in the study of amyloid Î²-protein assembly. Alzheimer's Research and Therapy, 2013, 5, 39.	3.0	64
39	Amyloid Î²-protein oligomers and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2013, 5, 60.	3.0	209
40	Factors That Drive Peptide Assembly and Fibril Formation: Experimental and Theoretical Analysis of Sup35 NNQQNY Mutants. Journal of Physical Chemistry B, 2013, 117, 8436-8446.	1.2	24
41	Mechanism of amyloid Î²â^'protein dimerization determined using singleâ^'molecule AFM force spectroscopy. Scientific Reports, 2013, 3, 2880.	1.6	66
42	1Î±,25-Dihydroxyvitamin D3 and Resolvin D1 Retune the Balance between Amyloid-Î² Phagocytosis and Inflammation in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2013, 34, 155-170.	1.2	109
43	The exception makes the rule. Neurology, 2012, 79, 206-207.	1.5	7
44	Preface. Progress in Molecular Biology and Translational Science, 2012, 107, xiii-xiv.	0.9	4
45	Preparation of Stable Amyloid Î²-Protein Oligomers of Defined Assembly Order. Methods in Molecular Biology, 2012, 849, 23-31.	0.4	19
46	Quasielastic Light Scattering Study of Amyloid Î²-Protein Fibrillogenesis. Methods in Molecular Biology, 2012, 849, 69-83.	0.4	7
47	Familial Alzheimerâ€™s Disease Mutations Differentially Alter Amyloid Î²-Protein Oligomerization. ACS Chemical Neuroscience, 2012, 3, 909-918.	1.7	80
48	Continuous Flow Reactor for the Production of Stable Amyloid Protein Oligomers. Biochemistry, 2012, 51, 6342-6349.	1.2	8
49	Structural Dynamics of the Amyloid Î²-Protein Monomer Folding Nucleus. Biochemistry, 2012, 51, 3957-3959.	1.2	15
50	Effect of melatonin on Î±-synuclein self-assembly and cytotoxicity. Neurobiology of Aging, 2012, 33, 2172-2185.	1.5	77
51	Brain-Targeted Proanthocyanidin Metabolites for Alzheimer's Disease Treatment. Journal of Neuroscience, 2012, 32, 5144-5150.	1.7	188
52	Alzheimer's Disease and the Amyloid Î²-Protein. Progress in Molecular Biology and Translational Science, 2012, 107, 101-124.	0.9	106
53	Dynamics of Metastable Î²-Hairpin Structures in the Folding Nucleus of Amyloid Î²-Protein. Journal of Physical Chemistry B, 2012, 116, 6311-6325.	1.2	28
54	Phenolic Compounds Prevent Amyloid Î²-Protein Oligomerization and Synaptic Dysfunction by Site-specific Binding. Journal of Biological Chemistry, 2012, 287, 14631-14643.	1.6	208

#	Article	IF	Citations
55	Structural dynamics of the Î”E22 (Osaka) familial Alzheimerâ€™s disease-linked amyloid Î²-protein. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 98-107.	1.4	50
56	Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiology of Aging, 2011, 32, 2321.e1-2321.e12.	1.5	54
57	Two Distinct Amyloid Î²-Protein (AÎ²) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses. Journal of Biological Chemistry, 2011, 286, 11555-11562.	1.6	102
58	Cerebrospinal Fluid from Alzheimer's Disease Patients Promotes Amyloid Î²-Protein Oligomerization. Journal of Alzheimer's Disease, 2010, 21, 81-86.	1.2	9
59	Effects of the English (H6R) and Tottori (D7N) Familial Alzheimer Disease Mutations on Amyloid Î²-Protein Assembly and Toxicity. Journal of Biological Chemistry, 2010, 285, 23186-23197.	1.6	131
60	Elucidation of Amyloid Î²-Protein Oligomerization Mechanisms: Discrete Molecular Dynamics Study. Journal of the American Chemical Society, 2010, 132, 4266-4280.	6.6	231
61	Grape Derived Polyphenols Attenuate Tau Neuropathology in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 653-661.	1.2	115
62	Amino Acid Position-specific Contributions to Amyloid Î²-Protein Oligomerization. Journal of Biological Chemistry, 2009, 284, 23580-23591.	1.6	79
63	Isolation and Characterization of Patient-derived, Toxic, High Mass Amyloid Î²-Protein (AÎ²) Assembly from Alzheimer Disease Brains. Journal of Biological Chemistry, 2009, 284, 32895-32905.	1.6	162
64	Amyloid Î²-Protein Assembly and Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 4749-4753.	1.6	564
65	Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathologica, 2009, 117, 111-124.	3.9	99
66	Amyloid-Î² protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nature Chemistry, 2009, 1, 326-331.	6.6	835
67	A facile method for expression and purification of the Alzheimerâ€™s diseaseâ€associated amyloid Î²â€peptide. FEBS Journal, 2009, 276, 1266-1281.	2.2	237
68	Amyloid Î²-Protein: Experiment and Theory on the 21â^’30 Fragment. Journal of Physical Chemistry B, 2009, 113, 6041-6046.	1.2	50
69	Amyloid Î² Protein: AÎ²40 Inhibits AÎ²42 Oligomerization. Journal of the American Chemical Society, 2009, 131, 6316-6317.	6.6	106
70	A Peptide Hairpin Inhibitor of Amyloid Î²-Protein Oligomerization and Fibrillogenesis. Biochemistry, 2009, 48, 11329-11331.	1.2	53
71	Structureâ€“neurotoxicity relationships of amyloid Î²-protein oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14745-14750.	3.3	701
72	On the nucleation of amyloid Î²-protein monomer folding. Protein Science, 2009, 14, 1581-1596.	3.1	310

#	Article	IF	Citations
73	Identification of Antihypertensive Drugs Which Inhibit Amyloid-Î² Protein Oligomerization. Journal of Alzheimer's Disease, 2009, 16, 49-57.	1.2	67
74	Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer's Disease-type Neuropathology and Cognitive Deterioration. Journal of Alzheimer's Disease, 2009, 16, 59-72.	1.2	116
75	Effects of the Arctic (E²²â†'G) Mutation on Amyloid Î²-Protein Folding: Discrete Molecular Dynamics Study. Journal of the American Chemical Society, 2008, 130, 17413-17422.	6.6	73
76	Effects of Familial Alzheimerâ€™s Disease Mutations on the Folding Nucleation of the Amyloid Î²-Protein. Journal of Molecular Biology, 2008, 381, 221-228.	2.0	96
77	Amyloid Î²-Protein Monomer Folding: Free-Energy Surfaces Reveal Alloform-Specific Differences. Journal of Molecular Biology, 2008, 384, 450-464.	2.0	219
78	Intramembrane Proteolysis of GXGD-type Aspartyl Proteases Is Slowed by a Familial Alzheimer Disease-like Mutation. Journal of Biological Chemistry, 2008, 283, 30121-30128.	1.6	34
79	Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease. Current Pharmaceutical Design, 2008, 14, 3231-3246.	0.9	107
80	Effects of Grape Seed-derived Polyphenols on Amyloid Î²-Protein Self-assembly and Cytotoxicity*. Journal of Biological Chemistry, 2008, 283, 32176-32187.	1.6	177
81	Grape-Derived Polyphenolics Prevent AÂ Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2008, 28, 6388-6392.	1.7	339
82	The Tottori (D7N) and English (H6R) Familial Alzheimer Disease Mutations Accelerate AÎ² Fibril Formation without Increasing Protofibril Formation. Journal of Biological Chemistry, 2007, 282, 4916-4923.	1.6	96
83	Familial Alzheimer's disease mutations alter the stability of the amyloid Î²-protein monomer folding nucleus. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16522-16527.	3.3	120
84	Role of Electrostatic Interactions in Amyloid Î²-Protein (AÎ²) Oligomer Formation: A Discrete Molecular Dynamics Study. Biophysical Journal, 2007, 92, 4064-4077.	0.2	108
85	Elucidating Amyloid Î²-Protein Folding and Assembly:â€‰ A Multidisciplinary Approach. Accounts of Chemical Research, 2006, 39, 635-645.	7.6	203
86	Common threads in neurodegenerative disorders of aging. , 2006, 2, 322-326.		6
87	Preparation of Amyloid Î²â€Protein for Structural and Functional Studies. Methods in Enzymology, 2006, 413, 20-33.	0.4	164
88	Towards Inhibition of Amyloid Î²-protein Oligomerization. , 2006, , 515-516.		1
89	Munumbicins E-4 and E-5: novel broad-spectrum antibiotics fromStreptomycesNRRL 3052. FEMS Microbiology Letters, 2006, 255, 296-300.	0.7	87
90	A Î³-secretase-like intramembrane cleavage of TNFÎ± by the GxGD aspartyl protease SPPL2b. Nature Cell Biology, 2006, 8, 894-896.	4.6	130

#	Article	IF	Citations
91	Amyloid beta-protein monomer structure: A computational and experimental study. Protein Science, 2006, 15, 420-428.	3.1	236
92	Structure of the 21-30 fragment of amyloid Î²-protein. Protein Science, 2006, 15, 1239-1247.	3.1	140
93	Computer Simulations of Alzheimers Amyloid β-Protein Folding and Assembly. Current Alzheimer Research, 2006, 3, 493-504.	0.7	36
94	Quasielastic Light Scattering Study of Amyloid β-Protein Fibril Formation. Protein and Peptide Letters, 2006, 13, 247-254.	0.4	16
95	Determination of Peptide Oligomerization State Using Rapid Photochemical Crosslinking. , 2005, 299, 011-018.		22
96	Quasielastic Light Scattering for Protein Assembly Studies. , 2005, 299, 153-174.		44
97	Preparation of Aggregate-Free, Low Molecular Weight Amyloid-Î² for Assembly and Toxicity Assays. , 2005, 299, 003-010.		51
98	Folding events in the 21-30 region of amyloid Â-protein (AÂ) studied in silico. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6015-6020.	3.3	122
99	Solvent and mutation effects on the nucleation of amyloid Â-protein folding. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18258-18263.	3.3	113
100	Conformational Dynamics of Amyloid Î²-Protein Assembly Probed Using Intrinsic Fluorescenceâ€. Biochemistry, 2005, 44, 13365-13376.	1.2	60
101	Neurotoxic protein oligomersâ€Šâ€”â€Šwhat you see is not always what you get. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 88-95.	1.4	208
102	Amyloid Î²-Protein:Â Monomer Structure and Early Aggregation States of AÎ²42 and Its Pro19Alloform. Journal of the American Chemical Society, 2005, 127, 2075-2084.	6.6	321
103	Coronamycins, peptide antibiotics produced by a verticillate Streptomyces sp. (MSU-2110) endophytic on Monstera sp.. Microbiology (United Kingdom), 2004, 150, 785-793.	0.7	189
104	In silico study of amyloid Â-protein folding and oligomerization. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17345-17350.	3.3	327
105	Rapid Photochemical Cross-Linking â€" A New Tool for Studies of Metastable, Amyloidogenic Protein Assemblies. ChemInform, 2004, 35, no.	0.1	1
106	Rapid Photochemical Cross-LinkingA New Tool for Studies of Metastable, Amyloidogenic Protein Assemblies. Accounts of Chemical Research, 2004, 37, 357-364.	7.6	204
107	Small assemblies of unmodified amyloid Î²-protein are the proximate neurotoxin in Alzheimerâ€™s disease. Neurobiology of Aging, 2004, 25, 569-580.	1.5	475
108	Amyloid Â-protein (AÂ) assembly: AÂ40 and AÂ42 oligomerize through distinct pathways. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 330-335.	3.3	1,208

#	Article	IF	Citations
109	A Molecular Switch in Amyloid Assembly:â€‰Met35 and Amyloid Î²-Protein Oligomerization. Journal of the American Chemical Society, 2003, 125, 15359-15365.	6.6	158
110	Kinetics of Amyloid Î²-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays. Journal of Biological Chemistry, 2003, 278, 37314-37320.	1.6	106
111	A Direct Interaction between Transforming Growth Factor (TGF)-Î²s and Amyloid-Î² Protein Affects Fibrillogenesis in a TGF-Î²Receptor-independent Manner. Journal of Biological Chemistry, 2003, 278, 38715-38722.	1.6	22
112	Elucidation of Primary Structure Elements Controlling Early Amyloid Î²-Protein Oligomerization. Journal of Biological Chemistry, 2003, 278, 34882-34889.	1.6	272
113	Structure determination of micelle-like intermediates in amyloid Â-protein fibril assembly by using small angle neutron scattering. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 150-154.	3.3	182
114	Kinetic Studies of Amyloid Î²-Protein Fibril Assembly. Journal of Biological Chemistry, 2002, 277, 36948-36954.	1.6	315
115	Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. Journal of Neuroscience Research, 2002, 69, 567-577.	1.3	540
116	A non-amyloidogenic function of BACE-2 in the secretory pathway. Journal of Neurochemistry, 2002, 81, 1011-1020.	2.1	99
117	Identification and characterization of key kinetic intermediates in amyloid Î²-protein fibrillogenesis11Edited by F. Cohen. Journal of Molecular Biology, 2001, 312, 1103-1119.	2.0	667
118	Presenilinâ€dependent Î³â€secretase processing of Î²â€amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Reports, 2001, 2, 835-841.	2.0	457
119	The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced AÎ² protofibril formation. Nature Neuroscience, 2001, 4, 887-893.	7.1	1,042
120	In vitro studies of amyloid Î²-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692â†'Gly) Alzheimer's disease. Biochemical Journal, 2001, 355, 869-877.	1.7	107
121	Amyloid Î²-Protein Oligomerization. Journal of Biological Chemistry, 2001, 276, 35176-35184.	1.6	362
122	A de novo designed helix-turn-helix peptide forms nontoxic amyloid fibrils. Nature Structural Biology, 2000, 7, 1095-1099.	9.7	122
123	An improved method of preparing the amyloid Î²-protein for fibrillogenesis and neurotoxicity experiments. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 166-178.	1.4	232
124	Protofibrillar Intermediates of Amyloid Î²-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons. Journal of Neuroscience, 1999, 19, 8876-8884.	1.7	926
125	[27] Monitoring protein assembly using quasielastic light scattering spectroscopy. Methods in Enzymology, 1999, 309, 429-459.	0.4	85
126	Cryptocandin, a potent antimycotic from the endophytic fungus Cryptosporiopsis cf. quercina. Microbiology (United Kingdom), 1999, 145, 1919-1926.	0.7	198

#	Article	IF	Citations
127	Amyloid Î²-Protein Fibrillogenesis. Journal of Biological Chemistry, 1999, 274, 25945-25952.	1.6	977
128	Structural and kinetic features of amyloid Î²-protein fibrillogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 121-142.	1.4	265
129	Enhanced Production and Oligomerization of the 42-residue Amyloid Î²-Protein by Chinese Hamster Ovary Cells Stably Expressing Mutant Presenilins. Journal of Biological Chemistry, 1997, 272, 7977-7982.	1.6	269
130	Amyloid Î²-Protein Fibrillogenesis. Journal of Biological Chemistry, 1997, 272, 22364-22372.	1.6	967
131	Aggregation of Secreted Amyloid Î²-Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture. Journal of Biological Chemistry, 1995, 270, 9564-9570.	1.6	345
132	Normal Cellular Processing of the Î²-Amyloid Precursor Protein Results in the Secretion of the Amyloid Î² Peptide and Related Moleculesa. Annals of the New York Academy of Sciences, 1993, 695, 109-116.	1.8	112
133	Amyloid Î²-peptide is produced by cultured cells during normal metabolism. Nature, 1992, 359, 322-325.	13.7	1,919